Paper Details

  1. Home
  2. Paper Details

[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].

Author: ChunFelix K H, HoehBenedikt, MandelPhilipp, WenzelMike

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Androgen deprivation therapy (ADT) has long been the standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). However, recent research has shown that combination therapies, including novel hormone therapies like androgen receptor-targeting agents (ARTAs) and docetaxel chemotherapy, are more effective than ADT alone. Triplet therapies, combining ADT with ARTAs and docetaxel, are also showing promise.
Paper Details　
Original Abstract of the Article :
Although androgen deprivation therapy (ADT) alone has been the standard of care (SOC) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) for decades, combination therapies of novel hormone therapy (androgen receptor-targeting agents [ARTA]) or docetaxel chemotherapy have more r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073052/

データ提供：米国国立医学図書館（NLM）

New Strategies for Metastatic Hormone-Sensitive Prostate Cancer

In the world of [Oncology], we face the challenge of treating [metastatic hormone-sensitive prostate cancer (mHSPC)]. This research explores new approaches to managing this complex condition, focusing on [androgen deprivation therapy (ADT) plus chemotherapy +/- androgen receptor-targeting agents (ARTA)].

While [ADT] has been the standard of care for decades, new combinations of therapies involving ARTA or docetaxel chemotherapy have shown promise in improving outcomes. Furthermore, the research explores the potential benefits of [triplet therapies with ADT plus ARTA (abiraterone/darolutamide) and docetaxel chemotherapy].

A Multi-pronged Approach

This research highlights the growing complexity of mHSPC treatment strategies. By combining multiple therapies, researchers are attempting to target this disease from various angles, like a team of camels working together to move a heavy load.

Seeking Better Outcomes

This research holds promise for improving the treatment of mHSPC. The development of new combinations of therapies offers hope for patients, and further research in this area is crucial to finding better treatments and improving outcomes.

Dr. Camel's Conclusion

This study underscores the evolving nature of mHSPC treatment, with a shift toward combination therapies that target the disease from multiple angles. This innovative approach holds promise for improving outcomes for patients with this complex condition.

Date :
  1. Date Completed 2023-04-06
  2. Date Revised 2023-04-11
Further Info :

Pubmed ID

36763112

DOI: Digital Object Identifier

PMC10073052

Related Literature

Article Analysis
・Side Effects of abiraterone
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.